News-Medical.Net October 16, 2024
Dr. Chinta Sidharthan

As AI technology evolves rapidly, the FDA is tackling the challenge of balancing innovation with patient safety, shaping regulations that ensure AI tools remain effective throughout their entire lifecycle.

A Special Communication published in the Journal of the American Medical Association (JAMA) examined the regulation of artificial intelligence (AI) in healthcare by the United States (U.S.) Food and Drug Administration (FDA). It also explored AI’s potential in clinical research, development of medical products, and patient care while highlighting the key areas to address as regulations are adapted for some of AI’s distinctive challenges in biomedicine and healthcare.

Background

Advances in AI have immense potential for transforming biomedicine and healthcare. Expectations from AI often exceed those from previous medical technologies such...

Today's Sponsors

Venturous
ZeOmega

Today's Sponsor

Venturous

Continue Reading

 
Topics: AI (Artificial Intelligence), FDA, Govt Agencies, Healthcare System, Patient / Consumer, Provider, Regulations, Safety, Technology
Related Articles:
FDA guidance eases wearables oversight. But experts have questions about what’s next.
AI Model FDA-Cleared to Triage 14 Conditions
The Promise And Perils Of FDA’s New ‘Plausible Mechanism’ Pathway (Part 2)
FDA Updates Two Digital Health Final Guidance Documents
FDA in Flux — January 2026 Newsletter

Share Article